An mRNA-based #mRNA vaccine to prevent #PancreaticCancer from returning shows promising results in a group of 16 patients.

Jyves94· @jyves94 · X·2026-04-20 03:00· 2026-04-20Score60

Reading

Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T

Personalized mRNA vaccines are simpler on paper: sequence the tumor, build a shot, add a PD-L1 antibody and chemotherapy. MSK’s autogene cevumeran showed responders living more than three times as long as non-responders.

Body

An mRNA-based #mRNA vaccine to prevent #PancreaticCancer from returning shows promising results in a group of 16 patients.

New results from a phase 1 clinical trial, presented at #AACR26 , show nearly 90% of patients still alive 6 years later.

Heat 6 · 4 likes · 0 replies · 2 reposts

Conference abstracts

CT122matched by 药名 tislelizumab

First-in-human (FIH) study of EVM16, a personalized mRNA neoantigen vaccine, as monotherapy and combination with tislelizumab in advanced solid tumors

Tong Xie, Jian Zhang, Yanchun Meng, Xu Jia, Yue Fan, Li Wang, Jennifer Yang, Sandra Zeng, Hongxia Wang, Lin Shen

Read the abstract →

Source: Jyves94 · x.com